Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK2 | Q15119 | 1/20 | 0.34 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | SMYD2 | Q9NRG4 | 1/20 | 0.32 |
| ▸ | PER2 | O15055 | 1/20 | 0.32 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4940595 | 1.00 | PDK2 (0.34) | PDK2BRD4SMYD2PER2GRIN2B | |
| SCHEMBL14270966 | 0.76 | POLB (0.37) | PDK2BRD4PER2GRIN2B | |
| SCHEMBL4941828 | 0.71 | PTGER4 (0.43) | — | |
| SCHEMBL12432872 | 0.71 | ALDH1A1 (0.46) | — | |
| SCHEMBL2213020 | 0.70 | GAA (0.47) | — | |
| SCHEMBL4375210 | 0.68 | PTGER4 (0.38) | PDK2BRD4 | |
| SCHEMBL4375203 | 0.68 | PTGER4 (0.38) | PDK2BRD4 | |
| SCHEMBL1712652 | 0.68 | PDK2 (0.39) | PDK2BRD4GRIN2B | |
| SCHEMBL5991525 | 0.68 | POLB (0.38) | BRD4GRIN2B | |
| SCHEMBL5766710 | 0.68 | PTGER4 (0.37) | PDK2BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080058375-A1 | Bone disorders; osteoporosis; antihistamines; sexual disorders; antiinflammatory agents; antiarthritic agents; vision defects; antiulcer agents | ELWORTHY TODD R | 2008-03-06 | — | — | US | disclosed |
| US-20080058375-A1 | Bone disorders; osteoporosis; antihistamines; sexual disorders; antiinflammatory agents; antiarthritic agents; vision defects; antiulcer agents | ELWORTHY TODD R | 2008-03-06 | — | — | US | disclosed |
| US-7271183-B2 | 2-Piperidone derivatives as prostaglandin agonists | ROCHE PALO ALTO LLC (US) | 2007-09-18 | — | — | US | disclosed |
| US-7271183-B2 | 2-Piperidone derivatives as prostaglandin agonists | ROCHE PALO ALTO LLC (US) | 2007-09-18 | — | — | US | disclosed |
| EP-1585729-A1 | 2-PIPERIDONE DERIVATIVES AS PROSTAGLANDIN AGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2005-10-19 | — | — | EP | disclosed |
| WO-2004063158-A1 | 2-PIPERIDONE DERIVATIVES AS PROSTAGLANDIN AGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2004-07-29 | — | — | WO | disclosed |
| US-20040142969-A1 | 2-Piperidone derivatives as prostaglandin agonists | ROCHE PALO ALTO LLC | 2004-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058375-A1 | Bone disorders; osteoporosis; antihistamines; sexual disorders; antiinflammatory agents; antiarthritic agents; vision defects; antiulcer agents | C3AR1, C1R, HRH4 | PDK2 4696/4885BRD4 4234/4885SMYD2 1403/4885 |
| US-20040142969-A1 | 2-Piperidone derivatives as prostaglandin agonists | PTGER1, PTGER2, PTGER4 | PDK2 2432/4885BRD4 2935/4885SMYD2 3678/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.